THIS IS HUGE: Snoop Dogg Enters Israeli Cannabis Industry!
Snoop Dogg is well-known for his advocacy of cannabis rights, so we were not surprised to see that he decided to partner with a company in Israel, which is a hub of innovation. Canada is first western nation to fully legalize cannabis, so its entrepreneurs are some of the most experienced in building companies and raising capital, but when it comes to a ground floor opportunity, in a market that is just getting off the launch pad, Israel is one of the next frontiers for cannabis technology.
In fact, much of the world’s cutting-edge medical cannabis research is coming directly out of Israel, and in September of last year, former Israeli Prime Minister Ehud Barak announced that he joined medical cannabis firm InterCure as chairman of the company. Ehud Olmert, another former Israeli Prime Minister, joined medical cannabis firm Univo Pharmaceuticals in April as an adviser and investor.
Israel is a cannabis mecca, as the country has the ideal climate and an eager consumer base.
With 10,000 patients on a waiting list for medical cannabis due to supply constraints, and the number of patients expected to exceed 50,000 this year, Israel could easily surpass Canada as the best pot-stock opportunity for sophisticated investors!
The incredible movement in the share price of IsraCann Biosciences (CSE: IPOT), the first PURE-PLAY Canadian-listed Israeli stock is proof positive that the Israeli cannabis market is poised for massive gains. Snoop Dogg clearly agrees with this, as he’s put his name and his brand behind a potentially game-changing product that’s coming right out of Israel.
Snoop Dogg is now a brand ambassador for Seedo and its “grow box” technology.
93% Of Investors Generate Annual Returns, Which Barely Beat Inflation.
Wealth Education and Investment Principles Are Hidden From Public Database On Purpose!
Build The Knowledge Base To Set Yourself Up For A Wealthy Retirement and Leverage The Relationships We Are Forming With Proven Small-Cap Management Teams To Hit Grand-Slams!
He’s been a cultural influencer for many years, and Snoop Dogg’s seal of approval carries a great deal of weight in the cannabis market. It’s surely no coincidence, then, that upon the announcement of the Snoop Dogg-Seedo partnership, IPOT shares absolutely went on a tear.
Isracann’s (CSE: IPOT) ambitious growth strategy has the EU in its sights, as the company is targeting Germany, United Kingdom, Poland, and Denmark for its rapidly expanding distribution network. Israel already approved the framework for exports of medical cannabis in January 2019, enabling the nation – and Isracann – to prepare for shipping operations across the European continent.
Unlike Canada, the EU is an untapped market, with medical cannabis already available in 10 European countries. The population of Europe is over 740 million, which is twice the population of Canada and the United States, and the EU medical market is estimated to grow to $64 billion by 2028.
Both geographically and in terms of its forward-thinking legal framework, Israel is perfectly positioned to become the epicenter of legalized cannabis exports throughout the European continent. Isracann (CSE: IPOT), in particular, is ready to capitalize on this opportunity, as the company plans to make their facilities IMC-GAP/GSP certified so that the product will be export-ready.
It’s been said that whatever Snoop Dogg attaches his name to turns to gold – and now that he’s taking a stake in the Israeli cannabis niche, you can count on explosive growth as Isracann dominates Israel, and soon Europe, as the purest pot-stock play around.
Chief Editor, CrushTheStreet.com
Governments Have Amassed ungodly Debt Piles and Have Promised Retirees Unreasonable Amounts of Entitlements, Not In Line with Income Tax Collections. The House of Cards Is Set To Be Worse than 2008! Rising Interest Rates Can Topple The Fiat Monetary Structure, Leaving Investors with Less Than Half of Their Equity Intact!
Protect Yourself Now, By Building A Fully-Hedged Financial Fortress!
This work is based on SEC filings, current events, interviews, corporate press releases and what we’ve learned as financial journalists. It may contain errors and you shouldn’t make any investment decision based solely on what you read here. It’s your money and your responsibility. Information contained in this profile was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. The information herein is not intended to be personal legal or investment advice and may not be appropriate or applicable for all readers. Crush The Street has been compensated three hundred thousand dollars, directly by IsraCann Biosciences, for a marketing campaign. We have also participated in a private placement. If personal advice is needed, the services of a qualified legal, investment or tax professional should be sought.
Please read our full disclaimer at CrushTheStreet.com/